RxAnte Named One of New England’s Fastest-Growing Companies for the Second Consecutive Year 

Tori-120x120

RxAnte is honored to be recognized again as one of New England’s Fastest-Growing Companies by The Boston Globe in partnership with Statista, marking the company’s second consecutive year receiving the accolade.  This year, RxAnte climbed from No. 22 to No. 14 in the rankings, reflecting its continued growth and momentum.

This annual list highlights companies headquartered in the six New England states that have demonstrated remarkable revenue growth and sustained business momentum. The recognition underscores RxAnte’s continued expansion and leadership in the field of Pharmacy Care Management.

“Our inclusion on this list again is a testament to the dedication and innovation of the entire RxAnte team,” said Josh Benner, Founder and CEO. “We remain committed to supporting health plans, healthcare providers, and pharmacies as they seek to improve prescription medication use and patient outcomes.  Our team is proud to be recognized for that impact.” 

At the heart of RxAnte’s growth is a relentless focus on delivering solutions that combine advanced data science with practical clinical application. From patented software products to high-touch pharmacy services, RxAnte’s suite of solutions continues to help clients achieve measurable improvements in quality of care, total cost of care, and member experience.  

Achieving this honor for a second consecutive year reflects not only strong financial performance but also the company’s ongoing commitment to innovation, client success, and patient care.    

To read more about the full list of New England’s Fastest-Growing Companies, visit The Boston Globe’s ranking.  

Related Resources

04-02-2026

RxAnte Recognized by the Financial Times as One of the Americas’ Fastest-Growing Companies for the Second Consecutive Year

01-13-2026

RxAnte Announces Strategic Growth Investment from Primus Capital

01-12-2026

Impact of a Pharmacy Care Management Service on Cardiometabolic Medication Adherence and Resource Use for Medicare Advantage Beneficiaries